
Devidas Menon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4393720/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Health Insurance Exemptions for Older Ghanaians: Stakeholder Perspectives on Challenges Confronting an Ambitious Policy. Journal of Aging and Social Policy, 2022, , 1-19.	0.9	0
2	Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review. BMC Health Services Research, 2022, 22, 557.	0.9	14
3	Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review. BMC Health Services Research, 2022, 22, 646.	0.9	3
4	HTA decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	12
5	Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana. Social Science and Medicine, 2021, 270, 113659.	1.8	7
6	"Our Home Is a Muddy Structure― Perceptions of Housing and Health Risks Among Older Adults in Contrasting Neighborhoods in Ghana. Frontiers in Public Health, 2021, 9, 650861.	1.3	2
7	Health, quality of life, and wellbeing of older slum dwellers in sub-Saharan Africa: A scoping review. Global Public Health, 2020, 16, 1-19.	1.0	4
8	Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes. International Journal of Technology Assessment in Health Care, 2020, 36, 87-95.	0.2	21
9	Robot-assisted coronary artery bypass surgery: a systematic review and meta-analysis of comparative studies. Canadian Journal of Surgery, 2020, 63, E491-E508.	0.5	12
10	Tracing the Decisions That Shaped the Development of MyChart, an Electronic Patient Portal in Alberta, Canada: Historical Research Study. Journal of Medical Internet Research, 2020, 22, e17505.	2.1	11
11	Patient Portal Implementation and Uptake: Qualitative Comparative Case Study. Journal of Medical Internet Research, 2020, 22, e18973.	2.1	20
12	Capturing the Impact of Patient Portals Based on the Quadruple Aim and Benefits Evaluation Frameworks: Scoping Review. Journal of Medical Internet Research, 2020, 22, e24568.	2.1	15
13	Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada. Orphanet Journal of Rare Diseases, 2019, 14, 127.	1.2	4
14	The Introduction of New Non-Drug Health Technologies (NDTs) into Canadian Healthcare Institutions: Opportunities and Challenges. Healthcare Policy, 2019, 15, 95-106.	0.3	2
15	Decision-Making on New Non-Drug Health Technologies (NDTs) by Hospitals and Health Authorities in Canada. Healthcare Policy, 2019, 15, 82-94.	0.3	3
16	Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study. Patient, 2018, 11, 353-359.	1.1	6
17	A checklist for managed access programmes for reimbursement coâ€designed by Canadian patients and caregivers. Health Expectations, 2018, 21, 973-980.	1.1	6
18	Palliative care in the home: a scoping review of study quality, primary outcomes, and thematic component analysis. BMC Palliative Care, 2018, 17, 41.	0.8	23

Devidas Menon

#	Article	lF	CITATIONS
19	The Medical Devices Special Access Program in Canada: A Scoping Study. Healthcare Policy, 2018, 13, 40-57.	0.3	2
20	Explicating social values for resource allocation decisions on new cancer technologies: We, the jury, findâ⊄. Journal of Cancer Policy, 2017, 14, 5-10.	0.6	6
21	Ultra-orphan drugs: can we afford the price. Expert Opinion on Orphan Drugs, 2017, 5, 611-612.	0.5	1
22	Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet Journal of Rare Diseases, 2017, 12, 188.	1.2	21
23	Challenges with implementing malaria rapid diagnostic tests at primary care facilities in a Ghanaian district: a qualitative study. Malaria Journal, 2016, 15, 126.	0.8	36
24	DEFINING ELIGIBILITY CRITERIA FOR FUNDING POLICIES AROUND IN VITRO FERTILIZATION. International Journal of Technology Assessment in Health Care, 2015, 31, 426-433.	0.2	1
25	Assisted Reproductive Technologies in Alberta: An Economic Analysis to Inform Policy Decision-Making. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 1122-1130.	0.3	3
26	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. Healthcare Policy, 2015, 10, 24-46.	0.3	3
27	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. Healthcare Policy, 2015, 11, 15-32.	0.3	13
28	Health technology assessment: the journey continues. Cmaj, 2015, 187, E19-E20.	0.9	6
29	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. American Heart Journal, 2015, 169, 122-131.e22.	1.2	24
30	Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?. Patient, 2015, 8, 29-39.	1.1	23
31	Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle. Patient, 2015, 8, 103-117.	1.1	14
32	Introduction of a new health technology into a provincial health system. Healthcare Management Forum, 2015, 28, 210-214.	0.6	0
33	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. Healthcare Policy, 2015, 10, 24-46.	0.3	5
34	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. Healthcare Policy, 2015, 11, 15-32.	0.3	13
35	Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development. Reproductive Health, 2014, 11, 76.	1.2	26
36	Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. Journal of Cancer Policy, 2014, 2, 81-88.	0.6	14

Devidas Menon

#	Article	IF	CITATIONS
37	Transparency in Reimbursement Decisions: In Whose Best Interest?. Pharmacoeconomics, 2014, 32, 725-727.	1.7	0
38	An international survey of assisted reproductive technologies (ARTs) policies and the effects of these policies on costs, utilization, and health outcomes. Health Policy, 2014, 116, 238-263.	1.4	13
39	Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Canadian Urological Association Journal, 2013, 2, 1.	0.3	14
40	Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. PLoS ONE, 2013, 8, e80661.	1.1	86
41	Health Technology Funding Decision-Making Processes Around the World. Pharmacoeconomics, 2011, 29, 475-495.	1.7	64
42	To Fund or Not to Fund. Pharmacoeconomics, 2011, 29, 771-780.	1.7	30
43	Access with Evidence Development: An Approach to Introducing Promising New Technologies into Healthcare. Healthcare Management Forum, 2011, 24, 42-48.	0.6	7
44	Role of patient and public participation in health technology assessment and coverage decisions. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 75-89.	0.7	73
45	Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterology, 2010, 10, 111.	0.8	45
46	Access with Evidence Development Schemes. Pharmacoeconomics, 2010, 28, 143-152.	1.7	71
47	Funding the Unfundable. Pharmacoeconomics, 2010, 28, 113-142.	1.7	120
48	Principles of Design of Access with Evidence Development Approaches. Pharmacoeconomics, 2010, 28, 109-111.	1.7	37
49	The role of surgeons in identifying emerging technologies for health technology assessment. Canadian Journal of Surgery, 2010, 53, 86-92.	0.5	11
50	Health Technology Assessment in Canada: 20 Years Strong?. Value in Health, 2009, 12, S14-S19.	0.1	48
51	The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond. Value in Health, 2008, 11, 771-783.	0.1	95
52	Engaging the public in priorityâ€setting for health technology assessment: findings from a citizens' jury. Health Expectations, 2008, 11, 282-293.	1.1	97
53	Priority-setting for healthcare: Who, how, and is it fair?. Health Policy, 2007, 84, 220-233.	1.4	37
54	Cerebral protection devices for use during carotid artery angioplasty with stenting: A health technology assessment. International Journal of Technology Assessment in Health Care, 2006, 22, 119-129.	0.2	3

DEVIDAS MENON

#	Article	IF	CITATIONS
55	Bridging the "Know-Do―Gap in Healthcare Priority-Setting: What Role Has Academic Research Played?. Healthcare Management Forum, 2005, 18, 26-32.	0.6	5
56	Access to Drugs for Cancer. Canadian Journal of Public Health, 2005, 96, 454-458.	1.1	43
57	Inter-Provincial Variation in Government Drug Formularies. Canadian Journal of Public Health, 2001, 92, 307-312.	1.1	42
58	Pharmaceutical Cost Control In Canada: Does It Work?. Health Affairs, 2001, 20, 92-103.	2.5	27
59	HEALTH TECHNOLOGY ASSESSMENT IN CANADA A Decade in Review. International Journal of Technology Assessment in Health Care, 2000, 16, 896-902.	0.2	26
60	An Assessment of Health Technology Assessment in Canada. Canadian Journal of Public Health, 2000, 91, 120-120.	1.1	2
61	The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics, 1999, 15, 459-468.	1.7	42
62	The Development of a Health Technology Assessment Program: The Case of Alberta. International Journal of Technology Assessment in Health Care, 1995, 11, 93-101.	0.2	5
63	Evaluation of Cerebral Blood Flow in Arteriovenous Malformations by the Xenon 133 Inhalation Method. Canadian Journal of Neurological Sciences, 1979, 6, 411-416.	0.3	18
64	Regional Cerebral Blood Flow in Patients with Aneurysms: Estimation by Xenon 133 Inhalation. Canadian Journal of Neurological Sciences, 1978, 5, 301-305.	0.3	39